Zensar Tech Acquires US-Based BridgeView to Expand Healthcare Solutions

Zensar Technologies, a wholly owned subsidiary of Zensar Technologies Limited, on Wednesday, July 17, announced that it has entered into definitive agreements to acquire 100% membership interest in BridgeView Life Sciences.
 

Key Takeaways from Zensar Technologies Acquisition

• Zensar Technologies to acquire 100% membership interest in BridgeView Life Sciences.
• The upfront payment for the acquisition is USD 14.0 million, with a potential additional payment of up to USD 11.0 million by December 31, 2027.
• The acquisition is expected to be completed within 2-3 weeks.
• The acquisition is expected to bolster Zensar's Healthcare and Life Sciences (HLS) vertical. 
   

The acquisition is valued at $14 million upfront with potential further payments of up to $11 million based on performance and is scheduled to be finalised within 2-3 weeks, subject to usual closing conditions.
 

"Acquiring BridgeView Life Sciences aligns with our long-term growth strategy for our growing HLS practice. This acquisition deepens our services for existing clients and expands into new areas, especially for innovators and emerging pharma players underserved by technology,” Anant Goenka, Vice-Chairman of RPG Enterprises and Zensar Technologies said. 
 

The acquisition is expected to bolster Zensar's Healthcare and Life Sciences (HLS) vertical, allowing it to provide a more comprehensive variety of solutions to pharmaceutical, biotechnology, and medical device firms.
 

“Zensar's global reach and digital expertise will help us offer more solutions and reach a wider audience. This synergy allows us to address customers' transformational programs effectively, improving patient lives faster”, James Corbett, Co‐founder and COO, and Mihales Karasavas, Co‐founder and CCO of BridgeView Life Sciences LLC, said in a joint statement. 
 

About Zensar Technologies Limited

Zensar Technologies is a leading technology solutions company with a strong engineering pedigree. Headquartered in Pune, India, Zensar is part of the USD 4.4 billion RPG Group and serves over 145 global clients. Zensar, a publicly traded firm for over 50 years, has continually challenged the status quo with its strong technical capabilities, creativity, and speed.
 

With a workforce of over 10,500 employees across more than 30 global locations, Zensar delivers cutting-edge digital solutions, drives growth, and empowers clients to thrive and succeed in a constantly evolving world.
 

About BridgeView Life Sciences

BridgeView is a leading provider of cutting‐edge information technology and operations solutions for the life sciences industry, dedicated to empowering organisations with advisory, transformation and support services that drive efficiency, compliance and patient outcomes. With a focus on integrity, insights and innovation, BridgeView Life Sciences bridges the gap between life sciences organisations and their product launch, operational optimization and M&A goals.

You can check Zensar Technologies Ltd share price to make informed investment decision.